Foundation Medicine, Inc.
One Kendall Square
Suite B3501
Cambridge
Massachusetts
02139
United States
Tel: 617-418-2200
Fax: 617-418-2201
Website: http://www.foundationmedicine.com/
234 articles about Foundation Medicine, Inc.
-
Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use
1/9/2023
Foundation Medicine, Inc. today launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.
-
FoundationOne®Liquid CDx Receives FDA Approval as a Companion Diagnostic for Rozlytrek® (entrectinib)
1/4/2023
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne®Liquid CDx to be used as a companion diagnostic to identify patients with ROS1-positive non-small cell lung cancer (NSCLC), or patients with NTRK fusion-positive solid tumors, who do not have a tissue sample available and may be appropriate for treatment with Rozlytrek (entrectinib).
-
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care
9/21/2022
Foundation Medicine, Inc. and Day One Biopharmaceuticals today announced a collaboration to develop FoundationOne®CDx as a companion diagnostic for Day One’s lead investigational therapy, tovorafenib (DAY101).
-
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008
9/12/2022
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne ® CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008.
-
Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic Profiling to Advance Cancer Care
9/6/2022
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced that the company and its collaborators will present 14 abstracts at the 2022 European Society for Medical Oncology Congress being held virtually and in person in Paris from September 9-13, 2022.
-
Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine
8/8/2022
Foundation Medicine, Inc., Flatiron Health, and Genentech, members of the Roche Group, in partnership with a network of community oncology practices, today announced new research in the Journal of Thoracic Oncology Clinical and Research Reports.
-
Foundation Medicine Announces Strategic Collaboration with Arvinas
6/5/2022
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced a collaboration with Arvinas, Inc., to develop FoundationOne®Liquid CDx as a companion diagnostic for use with Arvinas’ bavdegalutamide, an investigational novel PROTAC® protein degrader targeting the androgen receptor.
-
Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy
6/3/2022
LEADER Trial Will Use Results from Foundation Medicine’s Comprehensive Genomic Profiling Tests to Screen for Actionable Driver Mutations to Inform Trial Enrollment and Targeted Therapy Options for Patients.
-
Foundation Medicine and Collaborators to Share Scientific Advances at AACR22 Reinforcing the Power of Genomic Testing in Precision Cancer Care
4/5/2022
Foundation Medicine, Inc . today announced that the company and its collaborators will present a total of nine studies, including two clinical science symposia presentations and seven poster discussions, at the 2022 American Association for Cancer Research (AACR) Annual Meeting from April 8-13.
-
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer
3/17/2022
Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) EGFR exon 19 deletions or exon 21 (L858R) alterations and are appropriate for treatment with EGFR Tyrosine Kinase Inhibitors (TKI) approved by FDA for this indication.
-
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors
2/21/2022
Foundation Medicine’s tissue-based comprehensive genomic profiling test is now the first and only FDA-approved companion diagnostic to aid in identifying patients with MSI-H solid tumors who may benefit from immunotherapy.
-
Foundation Medicine’s ctDNA Monitoring Assay, FoundationOne®Tracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration
2/15/2022
Foundation Medicine’s ctDNA Monitoring Assay, FoundationOne ® Tracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration.
-
Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs
2/9/2022
Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO.
-
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
-
FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma
12/8/2021
Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx.
-
Foundation Medicine Appoints Dymeka Harrison as Chief Commercial Officer
10/13/2021
Foundation Medicine, Inc. today announced the appointment of Dymeka Harrison, MBA, as its Chief Commercial Officer.
-
Science 37® and Foundation Medicine Partner to Enable Interventional Home-Based Clinical Trials in Oncology
9/8/2021
Science 37 and Foundation Medicine today announced a collaboration to enable decentralized clinical research in oncology that will optimize recruitment and enrollment, improve patient retention, and expand access to precision cancer care.
-
BioSpace Movers & Shakers, Aug. 6
8/6/2021
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers. -
Foundation Medicine Appoints Sanket Agrawal as Chief BioPharma Business Officer
8/4/2021
Agrawal will oversee and expand collaborations with BioPharma organizations to support and accelerate the development of innovative cancer treatments
-
Foundation Medicine Collaborates on Research Published in The New England Journal of Medicine That Identifies Resistance to KRAS Inhibitors and Underscores Need for Novel Therapeutic Strategies
6/24/2021
Foundation Medicine, Inc. and its collaborators announced results from a Dana-Farber Cancer Institute-led study that used genomic testing, including Foundation Medicine’s liquid-based comprehensive genomic profiling test, FoundationOne®Liquid CDx, among several assays, to investigate resistance mechanisms in 38 patients with cancer treated with a KRAS G12C inhibitor.